
    
      PRIMARY OBJECTIVE: Evaluation of complete response rate on treatment combining FOLFIRINOX and
      panitumumab

      SECONDARY OBJECTIVE(S):

        -  Overall Survival

        -  Progression free survival

        -  Secondary resection

        -  Early tumor shrinkage (ETS)

        -  Depth of response (DpR)

        -  Safety profile (NCI-CTCAE v4.03 classification)

        -  Diagnostic performance of ccfDNA analysis compared to the tumor-tissue analysis (current
           gold standard)
    
  